<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892381</url>
  </required_header>
  <id_info>
    <org_study_id>13111993</org_study_id>
    <nct_id>NCT04892381</nct_id>
  </id_info>
  <brief_title>Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study</brief_title>
  <official_title>Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1&#xD;
      (PD-L1) Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective Case Control study will be conducted at Kasr Al-Aini Dermatology Outpatient&#xD;
      Clinics and will include 30 LP patients and 30 normal healthy controls which will be&#xD;
      recruited and assessed for eligibility for inclusion according to the above criteria.&#xD;
&#xD;
      All participants (patients &amp; controls) will be subjected to the following:&#xD;
&#xD;
        -  Written informed consent.&#xD;
&#xD;
        -  Detailed history including onset, course, duration of the disease and history of drug&#xD;
           intake within 1 month before the eruption.&#xD;
&#xD;
        -  Clinical assessment of the Severity by using LP Severity Index (LPSI) (Kaur et al.,&#xD;
           2020).&#xD;
&#xD;
        -  Skin biopsy will be taken under local anesthesia :&#xD;
&#xD;
        -  From each normal control; a 3 mm punch skin biopsy from a sun protected area will be&#xD;
           taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.&#xD;
&#xD;
        -  From each LP patient; two punch skin biopsies will be taken and preserved in PBS and&#xD;
           kept frozen at -80 degrees Celsius for ELISA study:&#xD;
&#xD;
           i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of&#xD;
           sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional&#xD;
           skin at least 15 cm away from the edge of any existing LP lesion of sun protected area&#xD;
&#xD;
        -  The level of PD1 and PD-L1 will be detected using ELISA technique.&#xD;
&#xD;
        -  The lesional biopsy will be assessed by routine hematoxylin and eosin (H&amp;E) to confirm&#xD;
           the diagnosis of LP&#xD;
&#xD;
        -  Patients' serial numbers only will be used on data collection sheets and ELISA&#xD;
           specimens' labels. Data will be entered on a computer with access limited to the&#xD;
           researchers in order to ensure confidentiality of patients' information and lab results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 18, 2021</start_date>
  <completion_date type="Anticipated">April 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Measurement of the level of PD-1 and PD-L1 in the lesional and in non lesional skin in LP patients compared to normal controls</measure>
    <time_frame>12 months</time_frame>
    <description>Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels in Lichen Planus Patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Lichen Planus group</arm_group_label>
    <description>Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA in lesional and non lesional skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin Biopsy</intervention_name>
    <description>Skin biopsy will be taken under local anesthesia :&#xD;
From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.&#xD;
From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:&#xD;
i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area&#xD;
The level of PD1 and PD-L1 will be detected using ELISA technique.&#xD;
The lesional biopsy will be assessed by routine hematoxylin and eosin (H&amp;E) to confirm the diagnosis of LP</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Lichen Planus group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  30 male and female Lichen Planus patients.&#xD;
&#xD;
          -  30 male and female normal healthy Controls. Patients will be selected from Kasr&#xD;
             Al-ainy, Dermatology Outpatient Clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age group above 18 years old&#xD;
&#xD;
          -  Patients of both genders&#xD;
&#xD;
          -  Classic type of cutaneous LP.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Topical treatment for LP 2 weeks before enrollment in the study or systemic treatment&#xD;
             for LP 4 weeks before enrollment in the study and 3 years for systemic retenoids.&#xD;
&#xD;
          -  Actinic LP , LP pigmentosus and Mucosal only LP&#xD;
&#xD;
          -  Drug induced lichenoid eruption&#xD;
&#xD;
          -  Conditions precluding taking skin biopsy : bleeding tendency , lidocaine allergy&#xD;
&#xD;
          -  PD-1 associated-diseases e.g.: SLE, Cancers including melanoma and non-melanoma skin&#xD;
             cancers, and Bullous Pemphigoid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rana A Misaad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rana A Mosaad, Msc</last_name>
    <phone>201096344429</phone>
    <email>ranaahmedmosaad@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aya M Fahim, MD</last_name>
    <phone>201141443447</phone>
    <email>ayafahim2011@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Rana A Mosaad, Msc</last_name>
      <phone>201096344429</phone>
      <email>ranaahmedmosaad@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aya M Fahim, MD</last_name>
      <phone>201141443447</phone>
      <email>ayafahim2011@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Aya Mohamed Fahim</investigator_full_name>
    <investigator_title>Dermatology Lecturer</investigator_title>
  </responsible_party>
  <keyword>LP</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

